第4名：BioGen制藥公司

????交易代碼: BIIB

????年初至今股票漲幅: 69%

????市值: 266億美元

????500強排名: 476

????制藥公司BioGen的股價上漲是源于其治療多發(fā)性硬化癥的藥物BG-12有希望獲得美國食品和藥物管理局（Food and Drug Administration）的批準,。

????BioGen開發(fā)治療多發(fā)性硬化癥,、癌癥和其他疾病的藥物。投資者最關注的是BioGen治療多發(fā)性硬化癥藥物的前景,，分析師們預測這款藥物的市場規(guī)?？赡芨哌_數(shù)十億美元。

????10月份,，BioGen宣布,，三期臨床試驗顯示,，服用BG-12的患者其多發(fā)性硬化癥復發(fā)率顯著下降。

????分析師們估計BG-12的市場規(guī)?？赡苓_到20-30億美元,，成為大多數(shù)多發(fā)性硬化癥患者的主要治療用藥。BioGen計劃2012年初向美國食品和藥物管理局提交新藥申報,。

????BG-12將豐富該公司現(xiàn)有的藥品組合,。憑借現(xiàn)有的藥品組合，BioGen第三季度凈利潤增長了38%,。

#4 BioGen

????Ticker: BIIB

????YTD stock performance: 69%

????Market cap: $26.6 billion

????Fortune 500 Rank: 476

????Shares of pharmaceutical maker BioGen spiked on hopes that the company could get its multiple sclerosis pill, BG-12, approved by the Food and Drug Administration.

????BioGen develops treatments for multiple sclerosis, cancer and other diseases. Investors are most focused on the prospects for BioGen's MS treatment as analysts have speculated that it could be a billion dollar drug.

????In October, BioGen said that patients using BG-12 during a third clinical trial showed significant drops in MS relapse rates.

????Analysts estimate that BG-12 could be a $2 billion to $3 billion drug, and become the primary treatment for most MS sufferers. BioGen plans to file for approval with the FDA in early 2012.

????BG-12 would round out the company's existing drug portfolio, which helped boost BioGen's third-quarter net income by 38%.